Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

NCT07233720 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Marginal Zone Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab

Sponsor

Henan Cancer Hospital